Summary:
In adults with STEMI undergoing primary PCI (stratified by BMI <25 vs ≥25 kg/m²), predominantly via radial access from the BRIGHT-4 trial, bivalirudin with prolonged high-dose infusion for 2-4 hours post-PCI demonstrated significant reduction in death or major bleeding in BMI <25 patients (3.2% vs 5.7%; HR 0.56) but no difference in BMI ≥25 patients (2.9% vs 2.9%) compared to heparin monotherapy during primary PCI without post-procedural infusion, with a statistically significant interaction between BMI and treatment effect (P-interaction = 0.04).
| PICO | Description |
|---|---|
| Population | 6,016 adults with STEMI undergoing primary PCI, stratified by BMI (<25 kg/m² vs ≥25 kg/m²), predominantly via radial access, from the BRIGHT-4 trial. |
| Intervention | Bivalirudin with prolonged high-dose infusion for 2-4 hours post-PCI. |
| Comparison | Heparin monotherapy during primary PCI without post-procedural infusion. |
| Outcome | In BMI <25: bivalirudin significantly reduced death or BARC 3-5 bleeding at 30 days (3.2% vs 5.7%; HR 0.56). In BMI ≥25: no significant difference (2.9% vs 2.9%; HR 0.97). Significant interaction (P=0.04). |
Clinical Context
Anticoagulation during primary PCI for STEMI requires balancing thrombotic and bleeding risks. The BRIGHT-4 trial demonstrated that bivalirudin with prolonged high-dose post-procedural infusion reduced the composite of death or major bleeding compared to heparin in STEMI patients.
This prespecified subgroup analysis examined whether the benefits of bivalirudin over heparin differ by BMI category.
Clinical Pearls
1. BMI Modifies Bivalirudin Benefit: The 44% relative risk reduction with bivalirudin in lower BMI patients (<25 kg/m²) contrasts sharply with the null effect in higher BMI patients. This interaction was prespecified and statistically significant.
2. Bleeding Drives the Difference: The benefit in lower BMI patients was primarily driven by reduced major bleeding events.
3. Higher BMI Patients Show No Harm: While bivalirudin didn’t provide benefit over heparin in patients with BMI ≥25 kg/m², it also didn’t cause harm.
4. Radial Access Context: The bivalirudin benefit in lower BMI patients persists even with radial access, suggesting the effect relates to systemic bleeding risk.
Practical Application
For STEMI patients with BMI <25 kg/m², consider preferentially using bivalirudin, particularly when bleeding risk is elevated. For patients with BMI ≥25 kg/m², either bivalirudin or heparin is reasonable.
Study Limitations
Subgroup analyses require cautious interpretation. The BMI cutoff of 25 kg/m² may not represent the optimal threshold. The predominantly Asian population with high radial access rates may limit generalizability.
Bottom Line
Bivalirudin with prolonged post-procedural infusion significantly reduces death or major bleeding compared to heparin in STEMI patients with BMI <25 kg/m², while showing no benefit or harm in patients with higher BMI.
Source: Zhang D, et al. “BMI Differences on Anticoagulation with Bivalirudin vs. Heparin During Primary PCI: A BRIGHT-4 Subanalysis.” Read article
